May 14, 2020 – Cellphire, the global leader in long-term stabilization and storage of platelets, announced today that the U.S. Food and Drug Administration (FDA) has granted an orphan drug designation for its platelet-based freeze-dried hemostatic, Thrombosomes®, for treatment of acute radiation syndrome (ARS).“The orphan drug designation is an important regulatory milestone as we further […]

(April 21, 2020) – Cellphire, Inc., the global leader in long-term stabilization and storage of platelets, announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, has exercised its third contract option valued […]

March 18, 2020 – Cellphire, Inc., the global leader in long-term stabilization and storage of platelets, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to start a Phase 2 clinical trial of Thrombosomes in bleeding patients with thrombocytopenia.In July 2019, Cellphire successfully completed a Phase I clinical trial […]

January 15, 2020 – Cellphire, the global leader in long-term stabilization and storage of platelets, announced today that the U.S. Army Medical Research Acquisition Activity (USAMRAA) has awarded the company a 6.5-year contract valued at $29.25 million (including all options) to develop a U.S. Food and Drug Administration (FDA) licensed dimethyl sulfoxide (DMSO) Cryopreserved Platelets […]

October 24, 2019 – Data from a phase 1, open-label, multi-center safety trial of lyophilized platelets were recently presented at the 2019 AABB Annual Meeting in San Antonio, Texas. Thrombosomes® (lyophilized platelets) are prepared from a pool of apheresis-derived human platelet units, pathogen-reduced with heat sterilization, and freeze-dried in the presence of trehalose (a naturally-derived […]

July 18, 2019 – Cellphire, Inc., the global leader in long-term cell stabilization and storage of platelets and other cells, announced today that the company completed enrollment of its Phase 1 clinical trial to evaluate Thrombosomes® in bleeding, thrombocytopenic patients. Thrombosomes is a freeze-dried hemostatic agent derived from human platelets.“The success in completing enrollment in […]

May 15, 2019 – Cellphire, Inc., the global leader in long-term stabilization and storage of platelets and other cells, announced today that John B. Holcomb, M.D., F.A.C.S., will serve as Medical Consultant.Dr. Holcomb has extensive experience in the treatment of military and civilian trauma patients and has led three major trauma clinical trials in the […]

February 27, 2019 — Cellphire, Inc., the global leader in long-term stabilization and storage of platelets and other cells, announced today that the Defense Advanced Research and Development Authority (DARPA) has awarded the company a seven-figure contract in conjunction with the University of North Carolina at Chapel Hill for Research Aimed to Extend the Golden […]

May 1, 2018 — Cellphire, Inc., the global leader in long-term stabilization and storage of platelets and other cells, announced today that Keith A. Moskowitz, Ph.D. MPM, has joined the company as Vice President of Discovery.  Dr. Moskowitz has more than two decades of leadership experience directing R&D, liaison and strategy in companies with revenues […]

March 1, 2018 — Cellphire, Inc., the global leader in long-term stabilization and storage of platelets and other cells, announced today that Heather Pidcoke, MD, MSCI, Ph.D., has joined the company as Chief Medical Officer.  Dr. Pidcoke’s translational research interests include trauma critical care and novel transfusion products aimed at improving the resuscitation of massively […]